The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.
The pharma company raised its guidance on revenue growth from its key treatments and expected drug launches, and now anticipates annual currency-adjusted sales to grow by 6% through 2028.